MOULDER LEON O JR
High convictionDirector, Chief Executive Officer · Zenas BioPharma, Inc.
Every open-market stock purchase MOULDER LEON O JR has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. Insiders sell for many reasons, but they buy with their own money for one — this page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- ZBIO+74.5% vs price paidZenas BioPharma, Inc.
15 purchases totalling $7.7M at an average of $16.05 per share; the stock last traded at $28.00. See all insider buying in ZBIO →
Avg price paid$16.05Latest price$28.00Market cap$1.8B
Cluster participation
Buys that landed within days of other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
| Date | Ticker | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| May 18, 2026 | 60,000 | $16.88 | $1.0M | SEC ↗ | |
| Apr 29, 2026 | 35,000 | $17.62 | $616.7K | SEC ↗ | |
| Apr 28, 2026 | 25,000 | $18.02 | $450.5K | SEC ↗ | |
| Mar 31, 2026 | ZBIOcluster | 34,000 | $19.31 | $656.5K | SEC ↗ |
| Mar 30, 2026 | ZBIOcluster | 20,000 | $18.23 | $364.6K | SEC ↗ |
| Feb 2, 2026 | ZBIOcluster | 57,000 | $17.96 | $1.0M | SEC ↗ |
| Jan 9, 2026 | 20,000 | $16.55 | $331.0K | SEC ↗ | |
| Jan 8, 2026 | 30,000 | $16.30 | $489.0K | SEC ↗ | |
| Jan 7, 2026 | 50,000 | $16.38 | $819.0K | SEC ↗ | |
| Oct 7, 2025 | ZBIOcluster | 36,928 | $20.85 | $769.9K | SEC ↗ |
| Feb 18, 2025 | 25,000 | $6.67 | $166.8K | SEC ↗ | |
| Dec 4, 2024 | 45,000 | $9.98 | $449.1K | SEC ↗ | |
| Dec 3, 2024 | 25,000 | $10.76 | $269.0K | SEC ↗ | |
| Nov 18, 2024 | 7,500 | $15.00 | $112.5K | SEC ↗ | |
| Sep 18, 2024 | ZBIOcluster | 10,000 | $17.91 | $179.1K | SEC ↗ |
Get alerted the next time MOULDER LEON O JR — or any insider — buys
We watch every Form 4 as it hits SEC EDGAR and alert you when insiders cluster into the same stock.
About this data
Figures are parsed from MOULDER LEON O JR's Form 4 filings on SEC EDGAR (CIK 1228865) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.